Analysis of the dynamics of changes in the economic availability of anticancer drugs used in the chemotherapy of lymphogralematosis in adults

Authors

DOI:

https://doi.org/10.24959/sphhcj.20.205

Keywords:

economic availability of anticancer drugs, lymphogranulomatosis, Hodgkin’s disease, anticancer drugs

Abstract

Aim. To analyze the changes in the indicators of economic availability of anticancer drugs used for the treatment of lymphogranulomatosis in Ukraine.

Materials and methods. The individual and group indices of average retail prices, the coefficients of the adequacy of the solvency and the economic availability of anticancer drugs at different levels of the ATC-classification system were studied. Historical, analytical-comparative, systemic, logical, hypothetical-deductive and other methods of scientific analysis and search were used.

Results. Based on the results of the analysis of the values and changes in the indicators of individual and group price indices for anticancer drugs an increase in the size of average retail prices in September 2020 was determined compared to the same period in 2019. Top three leading groups by the growth in the group price index in 2020 were drugs from the group of L01B – Antimetabolites, L01D – Cytotoxic antibiotics and related drugs, and L02A-Hormones and related substances. According to data of 2019, the group of leaders indicated included drugs representing L02A-Hormones and related substances, L01X – Other antineoplastic agents, L02B – Hormone antagonists and similar agents. It was proven that in 2020 the prices for drugs belonging to the groups of L02B – hormone antagonists and similar drugs increased to a lesser extent, and in 2019 - for L01C-plant alkaloids and other herbal drugs. The fact was determined that there was a decrease in the economic availability of anticancer drugs in 2020 compared to the indicators observed in 2019. Thus, for example, the average value of indicators for September 2019 was 4.75, and in 2020 – 5.38. The D indicator in 2019 was 1.20, while in 2020 it was only 0.79. It was proven that in 2020 practically for all groups of anticancer drugs in accordance with the level II of the ATC classification system a decrease in economic availability was observed. Thus, the least available drugs in 2020 were trade names from the group of L02B – hormone antagonists and similar drugs. An exception from this list was only drugs from the group of L01D – Cytotoxic antibiotics and related drugs (D = 1.01). According to the comparative analysis of the TOP-3 groups of anticancer drugs with the highest D values in 2019 and 2020, it was found that drugs of such groups as L01C-Alkaloids of plant origin and other drugs of plant origin and L01A – Alkylating compounds were present in both ratings.

Conclusions. Taking into account the negative trends towards a decrease in the level of economic availability of anticancer drugs in 2020 it is necessary to systematically consider the issues of strengthening the positions of the domestic drug manufacturer in this segment of the pharmaceutical market at the state level, primarily due to the introduction of state import substitution programs.

Author Biographies

H. L. Panfilova, National University of Pharmacy of the Ministry of Health of Ukraine

Doctor of Pharmacy (Dr. habil.), professor of the Department of Organization and Economics of Pharmacy

M. R. Matushchak, Bukovinian State Medical University

teaching assistant of the Department of Pharmaceutical Botany and Pharmacognosy

O. V. Tsurikova, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph. D.), teaching assistant of the Department of Мanagement, Еconomics and Quality Assurance in Pharmacy

I. A. Sokurenko, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph. D.), associate professor of the Department of Industrial Pharmacy and Economics of the Institute of Pharmacy Professionals Qualification Improvement

L. H. Boboshko, Donetsk National Medical University

teaching assistant of the Department of General and Biological Chemistry No. 1

References

Gobbi, P. G., Ferreri, A. J., Ponzoni, M., Levis, A. (2013). Hodgkin lymphoma. Crit Rev Oncol Hematol, 85 (2), 216-237. doi: 10.1016/j.critrevonc.2012.07.002.

Eyre, T. A., King, A. J., Collins, G. P. (2013). Classical Hodgkin’s lymphoma: past, present and future perspectives. British Journal of Hospital Medicine, 74 (11), 612-618. doi: 10.12968/hmed.2013.74.11.612.

Macalalad, A. R., McAuliffe, M., Yang, H., Kageleiry, A. et al. (2015). The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Current Medical Research & Opinion, 31 (3), 537-545. doi: 10.1185/03007995.2015.1008131.

Szabo, Sh. M., Hirji, I., Johnston, K. M., Juarez-Garcia, A. et al. (2017). Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study. PLoS ONE, 12 (10), e0180261. doi: https://doi.org/10.1371/journal. pone.0180261.

Houweling, T. A., Kunst, A. E. (2010). Socio-economic inequalities in childhood mortality in low- and middle-income countries: a review of the international evidence. Br Med Bull, 93, 7-26. doi: 10.1093/bmb/ldp048.

Abramson, J. S., Arnason, J. E., LaCasce, A. S. et al. (2019). Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood, 134 (7), 606-613. doi: 10.1182/blood.2019001272.

Connors, J. M., Jurczak, W., Straus, D. J. et al. (2018). Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med., 378 (4), 331-344. doi: 10.1056/NEJMoa1708984.

Ansell, S. M. (2020). Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. Am J Hematol., 95 (8), 978-989. doi: 10.1002/ajh.25856.

Ansell, S. M. (2016). Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol., 91 (4), 434-442. doi: 10.1002/ajh.24272.

Smith, E. C., Ziogas, A., Anton-Culver, H. (2012). Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer, 118, 6179-6187. doi: 10.1002/cncr.27684.

Kowalczyk, J. R., Agarwal, B., Ladenstein, R., Fitzgerald, E. et al. (2013). New policies to address the global burden of childhood cancers. Lancet Oncol., 14, 125-135. doi: 10.1016/S1470-2045(13)70007-X.

Albreht, T., Martin-Moreno, J. M., Jelenc, M., Gorgojo, L., Harris, M. (Eds.). (2015). European Guide for Quality National Cancer Control Programme. Slovenia, Ljubljana: National Institute of Public Health, 113.

Kontseptsiia “Zahalnoderzhavnoi prohramy borotby z onkolohichnymy zakhvoriuvanniamy na 2017-2022 roky”. Available at: http://unci.org.ua/wp-content/uploads/2017/02/%D0%9A%D0%BE%D0%BD%D1%86%D0%B5%D0%BF%D1%86%D1%96%D1%8F-%D0%BF%D1%80%D0%BE%D0%B3%D1%80%D0%B0%D0%BC%D0%B8-_%D0%9E%D0%BD%D0%BA%D0%BE%D0%BB%D0%BE%D0%B3%D1%96%D1%8F_pdf-1.pdf.

Kharakterystyka onkoepidemiolohichnoho protsesu ta stanu orhanizatsii protyrakovoi borotby v Ukraini v 2018-2019 rokakh. (2020). Biuleten Natsionalnoho Kantser-reiestru, 21. Available at: http://www.ncru.inf.ua/publications/BULL_21/PDF/vstup.pdf.

90% preparativ z prohramy dorosloi onkolohii sohodni zakupovuiut deshevshe nizh 2014 roku. Zvit TsPK. Available at: https://moz.gov.ua/article/news/90-preparativ-z-programi-dorosloi-onkologii-sogodni-zakupovujut-deshevshe-nizh-2014-roku---zvit-cpk.

Nemchenko A., Nazarkina V., Podgaina M., Nemchenko O. (2018). HTA of Pharmacotherapy оf Metastatic Prostate Cancer for Inclusion into the National List of the Essential Medicines. British Medical Bulletin, 128 (1 (2)), 216-227.

Yasenchak, C. A., Tseng, W. Y., Yap, M., Rembert, D., Patt, D. A. (2015). Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. Leuk Lymphoma, 56 (11), 3143–3149. doi: 10.3109/10428194.2015.1030639.

Eyre, T. A., King, A. J., Collins, G. P. (2013). Classical Hodgkin’s lymphoma: past, present and future perspectives. British Journal of Hospital Medicine, 74 (11), 612–618.

Mnushko, Z. N., Trufan, S. B. (2002). Provizor, 21, 18-25.

Nemchenko, A. S., Halii, L. V. (2002). Farmatsatsevtychnyi zhurnal, 4, 31-3

Published

2020-12-09

Issue

Section

Social medicine and pharmacy: past, present and development prospects